LILRB2 and lung carcinoma: Collectively, these results indicated that PIR-B and PD-L1 blockade synergistically normalized the immunosuppressive TME and prevented tumor growth and immune escape in vivo, rationalizing the combination of ILT4 and PD-L1 blockade in lung cancer treatment.